Prognostic Indicators of Survival in Sinonasal Diffuse LargeB‐CellLymphoma: A National Cancer Database Analysis
- 20 September 2021
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 132 (8) , 1515-1522
Abstract
Objectives/Hypothesis: This study offers an update on the epidemiologic and prognostic factors and treatment‐specific outcomes in patients diagnosed with sinonasal diffuse large B‐cell lymphoma (DLBCL).Study Design: Retrospective cohort study.Methods: National Cancer Database was queried from 2004 to 2016 for patients with sinonasal DLBCL. Univariate Kaplan‐Meier and multivariate Cox‐regression analyses were performed to evaluate the association of suspected prognostic factors with overall survival (OS).Results: A total of 2,222 patients with sinonasal DLBCL were analyzed. OS was 62% at 5 years and 42% at 10 years. Prognostic factors associated with increased survival included African‐American race (HR: 0.48, 95% CI: 0.33–0.70), chemotherapy (HR: 0.30, CI: 0.25–0.35), and radiation (HR: 0.80, CI: 0.69–0.93). Prognostic factors associated with decreased survival included patients with Charlson‐Deyo scores of 1 (HR: 1.51, CI: 1.25–1.84), 2 (HR: 2.25, CI: 1.67–3.03), and 3 (HR: 2.36, CI: 1.49–3.74) and patients with Lugano stage III (HR: 1.69, CI: 1.09–2.62) and IV (HR: 1.96, CI: 1.46–2.64) disease. Stage‐based split multivariate analysis was performed and revealed chemotherapy was independently associated with increased OS in patients with stage I (HR: 0.24, CI: 0.19–0.30), II (HR: 0.17, CI: 0.11–0.28), and IV (HR: 0.41, CI: 0.26–0.64) disease. Radiotherapy was independently associated with increased OS in patients with stage I disease only (HR: 0.67, CI: 0.55–0.83), while immunotherapy was an independent prognostic factor in patients with stage IV disease only (HR: 0.60, CI: 0.37–0.98).Conclusion: This study is the largest to date to analyze the association of demographic features and treatment modalities with OS in patients with sinonasal DLBCL. It is the first to investigate the association of immunotherapy with OS in this population. A combination treatment of immunochemotherapy or radioimmunochemotherapy confers increased survival, particularly in patients with advanced disease.Level of Evidence: 4Laryngoscope, 132:1515–1522, 2022Keywords
This publication has 31 references indexed in Scilit:
- Treatment of the elderly patient with diffuse large B cell lymphomaBritish Journal of Haematology, 2012
- Role of Functional Imaging in the Management of LymphomaJournal of Clinical Oncology, 2011
- Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research ConsortiumClinical Lymphoma Myeloma and Leukemia, 2010
- Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: Anatomic site and histology differencesCancer Epidemiology, 2009
- Diffuse Large B-Cell LymphomaHematology/Oncology Clinics of North America, 2008
- Non-Hodgkin Lymphoma: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1998
- Lymphoma of the nasal cavity and paranasal sinusesCancer, 1997